Dysmenorrhea Treatment Market: By Disease Type (Primary & Secondary Dysmennorhea), By Treatment Type (NSAIDs, Hormone Replacement Therapy, Surgery & Others) & By Region - Forecast(2018 - 2023)

Report Code : HCR 0284 Format Type: PDF+ Excel Database

Dysmenorrhea refers to painful menstruation. There are two types of Dysmenorrhea - primary and secondary. In Primary Dysmenorrhea recurrent and painful menstrual cramps occur one or two days before menstrual bleeding, and is felt in the lower abdomen, back, or thigh and is mild to severe in nature, typically lasting 12 to 72 hours. Nausea, vomiting, fatigue, and even diarrhea may also be seen in this type of condition. Primary Dysmenorrhea affects 45 and 95% of menstruating women.

Secondary Dysmenorrhea is characterized by pain, due to a disorder or infection in the woman's reproductive organs; the pain usually begins earlier in the menstrual cycle and lasts upto common menstrual cramps.

Various classes of drugs are used to treat Dysmenorrhea either as monotherpy or as combination therapy. Drug regimen is chosen based on Dysmenorrhea type. Non-steroidal anti-inflammatory drugs (NSAIDs), Glyceryl trinitrate, Progestin regimens and Levonorgestrel intrauterine system (LN-IUS). Surgical options like Laparoscopy, Hysterectomy, Presacral neurectomy, and Laparoscopic uterosacral nerve ablation are also available to treat the condition.

Globally, Dysmenorrhea affects 60-93% of women, of which more than 50% are post pubescent menstruating women. Major factors driving market of Dysmenorrhea are high consciousness level, government campaigns and growing concern about Dysmenorrhea among females. However, long term treatment, morbidity, and traditional family values would restrain the growth of market.

This report provides information on Dysmenorrhea treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to Dysmenorrhea treatment market.
Dysmenorrhea Treatment Market

Geographically, USA, Europe and Asia pacific are considered as the major markets for Dysmenorrhea. North America owing has high incidence of Dysmenorrhea. Europe is the second largest market with existence of a large number of Dysmenorrhea patients. North America and Europe have high healthcare spending, well established infrastructure, high awareness about the disease and high availability of its treatments.

Asia-Pacific is expected to have rapid growth in Dysmenorrhea treatment market because of changing infrastructure, educational program, increase in purchasing power, and increased awareness for clinical facilities in the regions. China, Japan, India are the emerging markets they have high market potential for Dysmenorrhea. In these countries growing awareness campaigns is enhancing the Dysmenorrhea treatment market.

This report identifies global Dysmenorrhea treatment market on the basis of type and regional market as follows:
  • Dysmenorrhea treatment market is segmented based on type primary and secondary
  • A detailed analysis by region – North America, Europe, Asia Pacific (APAC) and Rest of the World (RoW), has been provided in this report
Sample Companies Profiled in this Report are:
  • Novartis AG
  • Merck, Inc.
  • Bayer Schering Pharma AG,
  • Abbott Healthcare
  • Pfizer, Inc.
  • 10+


Request Sample Data